ANDREA HITTLE: Open Payments
NPI 1669051009 · RUSHVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,139 in 72 payments from 18 companies in 2025. Trend: 2023 $447 · 2024 $1,001 · 2025 $1,139
Food & beverage: $1,139
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $204 |
| Otsuka America Pharmaceutical, Inc. | 18 | $185 |
| PFIZER INC. | 9 | $166 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $122 |
| Novo Nordisk Inc | 4 | $66 |
| Vanda Pharmaceuticals Inc. | 3 | $64 |
| Lilly USA, LLC | 3 | $58 |
| Astellas Pharma US Inc | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Exact Sciences Corporation | 2 | $32 |
Products named: REXULTI, VRAYLAR, CAPLYTA, FANAPT, ELIQUIS, NURTEC ODT, Veozah, QULIPTA.
Industry payments across IN — which companies pay providers there.
